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(HIT) associated with severe thrombotic
events is a well-recognized complication of
heparin therapy. The frequency of HIT var-
ies widely in different reports and cumula-
tive data suggest a prevalence of about 1–5%
in patients treated with unfractionated hepa-
rin [1, 2]. In most cases HIT manifests with
platelet counts below 100 ! 103/ml within
5–10 days after heparin therapy. An immu-
nological mechanism has been emphasized
to be involved in the development of HIT
and thrombosis [3, 4]. It has been proposed
that heparin complexed to platelet factor 4
(PF4) is a target for IgG antibodies. The
immune complexes generated consist of hep-
arin, PF4 and IgG, bind to circulating plate-
lets via the Fc receptor and induce a cycle of
platelet activation and consumption. Para-
doxically, thromboembolic complications
may develop in some patients with HIT, pos-
sibly by in vivo platelet activation [5]. Based
on this hypothesis, an enzyme-linked immu-
nosorbent assay (ELISA) was recently devel-
oped to detect anti-PF4-heparin antibodies
in the serum of HIT patients [3].
The available data on the frequency of
HIT mainly concern patients receiving hepa-
rin during a relatively short period of time
[2]. Since patients on hemodialysis are re-
peatedly exposed to heparin, one might ex-
pect a higher frequency of heparin-depen-
dent antibodies associated with HIT in this
group of patients. In the present study we
investigated the prevalence of antibodies
against PF4-heparin complexes in patients
on regular hemodialysis. Patient characteris-
tics are outlined in table 1. All patients were
treated 3 times a week with unfractionated
heparin consisting of a single intravenous
bolus injection (1,000–5,000 IU) at the be-
ginning of each dialysis session followed by
continuous infusion (1,000–2,000 IU/h) for
4–5 h. Blood samples were collected at the
beginning of a hemodialysis session for
platelet counts. IgG antibodies to PF4-hepa-
rin complexes were detected by an ELISA as
described by Amiral et al. [3]. The results are
given as the optical density at 492 nm. Using
healthy subjects (n = 20, OD ! 0.25) and pos-
itive standards as controls, an OD 1 0.5 was
considered positive.
In only 1 of our patients was the platelet
count !100 ! 103/Ìl, but in this patient hep-
arin-induced antibodies were not detected.
However, anti-PF4-heparin IgG antibodies
were found in 2 patients (OD 0.6 and 1.6)
with normal platelet counts. None of the
2 patients had thromboembolic complica-
tions and no unexpected clot formation in
dialyzers or extracorporeal circuits was ob-
served during an observation period of 6
months following the blood sampling. In our
study the prevalence of IgG antibodies to
PF4-heparin complexes in patients with end-
stage renal failure on chronic hemodialysis
was 2.8%. The finding is consistent with a
previous report [6], where the prevalence of
heparin-dependent antibodies in hemodialy-
sis patients was 2.3% and the presence of
these antibodies was also not associated with
the clinical picture of HIT.
The prevalence of HIT seems to be high-
er at the beginning of hemodialysis treat-
ment. In 3.9% (6 of 154) of patients newly
treated with hemodialysis, Yamamoto et al.
[7] observed HIT with thromboembolic
events within 60 days after initiation of
treatment, and 5 of 6 patients had positive
levels of anti-PF4-heparin antibodies. Simi-
lar observations were made in orthopedic
patients who received low-dose heparin for
prophylaxis against deep venous thrombosis
[2]. In summary our data demonstrate that
hemodialysis patients, who are repeatedly
exposed to heparin over a long period of
time, have a low prevalence of antibodies to
PF4-heparin complexes. The clinical rele-
vance of these antibodies is as yet unknown
but their presence does not seem to be asso-
ciated with the clinical picture of HIT. How-
ever, the detection of heparin-dependent an-
tibodies seems to be relevant during the first
weeks after initiation of hemodialysis [7, 8].
Table 1. Characteristics of hemodialysis
patients
Number of patients 70
Sex
Male/female 41/29
Mean age, years (BSD) 54B13
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